Institute News: Announcements

Honoring a visionary

by McGovern Institute |

Today marks the 10th anniversary of the passing of Pat McGovern, an extraordinary visionary and philanthropist whose legacy continues to inspire and impact the world. As the founder of International Data Group (IDG)—a premier information technology organization—McGovern was not just a pioneering figure in the technology media world, but also a passionate advocate for using technology for the greater good.

Under McGovern’s leadership, IDG became a global powerhouse, launching iconic publications such as Computerworld, Macworld, and PCWorld. His foresight also led to the creation of IDG Ventures, a network of venture funds around the world, including the notable IDG Capital in Beijing.

Beyond his remarkable business acumen, McGovern, with his wife, Lore, co-founded the McGovern Institute for Brain Research at MIT in 2000. This institute has been at the forefront of neuroscience research, contributing to groundbreaking advancements in perception, attention, memory, and artificial intelligence (AI), as well as discoveries with direct translational impact, such as CRISPR technology. CRISPR discoveries made at the McGovern Institute are now licensed for the first clinical application of genome editing in sickle cell disease.

Pat McGovern’s commitment to bettering humanity is further evidenced by the Patrick J. McGovern Foundation, which works in partnership with public, private, and social institutions to drive progress on our most pressing challenges through the use of artificial intelligence, data science, and key emerging technologies.

Remembering Pat McGovern

On this solemn anniversary, we reflect on Pat McGovern’s enduring influence through the words of those who knew him best.

Lore Harp McGovern
Co-founder and board member of the McGovern Institute for Brain Research

“Technology was Pat’s medium, the platform on which he built his amazing company 60 years ago. But it was people who truly motivated Pat, and he empowered and encouraged them to reach for the stars. He lived by the motto, ‘let’s try it,’ and believed that nothing was out bounds. His goal was to help create a more just and peaceful world, and establishing the McGovern Institute was our way to give back meaningfully to this world. I know he would be so proud of what has been achieved and what is yet to come.”

Robert Desimone
Director of the McGovern Institute for Brain Research

“Pat McGovern had a vision for an international community of scientists and students drawn together to collaborate on understanding the brain.  This vision has been realized in the McGovern Institute, and we are now seeing the profound advances in our understanding of the brain and even clinical applications that Pat predicted would follow.”

Hugo Shong
Chairman of IDG Capital

“Pat’s impact on technology, science and research is immeasurable. A man of tremendous vision, he grew IDG out of Massachusetts and made it into one of the world’s most recognized brands in its space, forging partnerships and winning friends wherever he went. He applied that very same vision and energy to the McGovern Institute and the Patrick J. McGovern Foundation, in support of their impressive and necessary causes. I know he would be extremely proud of what both organizations have achieved thus far, and particularly how their work has broken technological frontiers and bettered the lives of millions.”

Vilas Dhar
President of the Patrick J. McGovern Foundation

“Patrick J. McGovern was more than a tech mogul; he was a visionary who believed in the power of information to empower people and improve societies. His work has had a profound effect on public policy and education, laying the groundwork for a more informed and connected world and guiding our work to ensure that artificial intelligence is used to sustain a human-centered world that creates economic and social opportunity for all.  On a personal level, Pat’s leadership was characterized by a genuine care for his employees and a belief in their potential. He created a culture of curiosity, encouraging humanity to explore, innovate, and dream big. His spirit lives on in every philanthropic activity we undertake.”

Genevieve Juillard
CEO of IDG 

“The legacy of Pat McGovern is felt not just in Boston, but around the world—by the thousands of IDG customers and by people like me who have the privilege to work at IDG, 60 years after he founded it. His innovative spirit and unwavering commitment to excellence continue to inspire and guide us.”

Sudhir Sethi
Founder and Chairman of Chiratae Ventures (formally IDG Ventures)

“Pat McGovern was a visionary who foresaw the potential of technology in India and nurtured the ecosystem as an active participant. Pat enabled a launchpad for Chiratae Ventures, empowering our journey to become the leading home-grown venture capital fund in India today. Pat is a role model to entrepreneurs worldwide, and we honor his legacy with our annual ‘Chiratae Ventures Patrick J. McGovern Awards’ that celebrate courage and the spirit of entrepreneurship.”

Marc Benioff
Founder and CEO of Salesforce wrote in the book “Future Forward that “Pat McGovern was a gift to us all, a trailblazing visionary who showed an entire generation of entrepreneurs what it means to be a principle-based leader and how to lead with higher values.”

Pat McGovern’s memory lives on not just in the institutions and innovations he fostered, but in the countless lives he touched and transformed. Today, we celebrate a man who saw the future and helped us all move towards it with hope and determination.

Simons Center’s collaborative approach propels autism research, at MIT and beyond

by David Orenstein |

The secret to the success of MIT’s Simons Center for the Social Brain is in the name. With a founding philosophy of “collaboration and community” that has supported scores of scientists across more than a dozen Boston-area research institutions, the SCSB advances research by being inherently social.

SCSB’s mission is “to understand the neural mechanisms underlying social cognition and behavior and to translate this knowledge into better diagnosis and treatment of autism spectrum disorders.” When Director Mriganka Sur founded the center in 2012 in partnership with the Simons Foundation Autism Research Initiative (SFARI) of Jim and Marilyn Simons, he envisioned a different way to achieve urgently needed research progress than the traditional approach of funding isolated projects in individual labs. Sur wanted SCSB’s contribution to go beyond papers, though it has generated about 350 and counting. He sought the creation of a sustained, engaged autism research community at MIT and beyond.

“When you have a really big problem that spans so many issues — a clinical presentation, a gene, and everything in between — you have to grapple with multiple scales of inquiry,” says Sur, the Newton Professor of Neuroscience in MIT’s Department of Brain and Cognitive Sciences (BCS) and The Picower Institute for Learning and Memory. “This cannot be solved by one person or one lab. We need to span multiple labs and multiple ways of thinking. That was our vision.”

In parallel with a rich calendar of public colloquia, lunches, and special events, SCSB catalyzes multiperspective, multiscale research collaborations in two programmatic ways. Targeted projects fund multidisciplinary teams of scientists with complementary expertise to collectively tackle a pressing scientific question. Meanwhile, the center supports postdoctoral Simons Fellows with not one, but two mentors, ensuring a further cross-pollination of ideas and methods.

Complementary collaboration

In 11 years, SCSB has funded nine targeted projects. Each one, by design, involves a deep and multifaceted exploration of a major question with both fundamental importance and clinical relevance. The first project, back in 2013, for example, marshaled three labs spanning BCS, the Department of Biology, and The Whitehead Institute for Biomedical Research to advance understanding of how mutation of the Shank3 gene leads to the pathophysiology of Phelan-McDermid Syndrome by working across scales ranging from individual neural connections to whole neurons to circuits and behavior.

Other past projects have applied similarly integrated, multiscale approaches to topics ranging from how 16p11.2 gene deletion alters the development of brain circuits and cognition to the critical role of the thalamic reticular nucleus in information flow during sleep and wakefulness. Two others produced deep examinations of cognitive functions: how we go from hearing a string of words to understanding a sentence’s intended meaning, and the neural and behavioral correlates of deficits in making predictions about social and sensory stimuli. Yet another project laid the groundwork for developing a new animal model for autism research.

SFARI is especially excited by SCSB’s team science approach, says Kelsey Martin, executive vice president of autism and neuroscience at the Simons Foundation. “I’m delighted by the collaborative spirit of the SCSB,” Martin says. “It’s wonderful to see and learn about the multidisciplinary team-centered collaborations sponsored by the center.”

New projects

In the last year, SCSB has launched three new targeted projects. One team is investigating why many people with autism experience sensory overload and is testing potential interventions to help. The scientists hypothesize that patients experience a deficit in filtering out the mundane stimuli that neurotypical people predict are safe to ignore. Studies suggest the predictive filter relies on relatively low-frequency “alpha/beta” brain rhythms from deep layers of the cortex moderating the higher frequency “gamma” rhythms in superficial layers that process sensory information.

Together, the labs of Charles Nelson, professor of pediatrics at Boston Children’s Hospital (BCH), and BCS faculty members Bob Desimone, the Doris and Don Berkey Professor of Neuroscience at MIT and director of the McGovern Institute, and Earl K. Miller, the Picower Professor, are testing the hypothesis in two different animal models at MIT and in human volunteers at BCH. In the animals they’ll also try out a new real-time feedback system invented in Miller’s lab that can potentially correct the balance of these rhythms in the brain. And in an animal model engineered with a Shank3 mutation, Desimone’s lab will test a gene therapy, too.

“None of us could do all aspects of this project on our own,” says Miller, an investigator in the Picower Institute. “It could only come about because the three of us are working together, using different approaches.”

Right from the start, Desimone says, close collaboration with Nelson’s group at BCH has been essential. To ensure his and Miller’s measurements in the animals and Nelson’s measurements in the humans are as comparable as possible, they have tightly coordinated their research protocols.

“If we hadn’t had this joint grant we would have chosen a completely different, random set of parameters than Chuck, and the results therefore wouldn’t have been comparable. It would be hard to relate them,” says Desimone, who also directs MIT’s McGovern Institute for Brain Research. “This is a project that could not be accomplished by one lab operating in isolation.”

Another targeted project brings together a coalition of seven labs — six based in BCS (professors Evelina Fedorenko, Edward Gibson, Nancy Kanwisher, Roger Levy, Rebecca Saxe, and Joshua Tenenbaum) and one at Dartmouth College (Caroline Robertson) — for a synergistic study of the cognitive, neural, and computational underpinnings of conversational exchanges. The study will integrate the linguistic and non-linguistic aspects of conversational ability in neurotypical adults and children and those with autism.

Fedorenko said the project builds on advances and collaborations from the earlier language Targeted Project she led with Kanwisher.

“Many directions that we started to pursue continue to be active directions in our labs. But most importantly, it was really fun and allowed the PIs [principal investigators] to interact much more than we normally would and to explore exciting interdisciplinary questions,” Fedorenko says. “When Mriganka approached me a few years after the project’s completion asking about a possible new targeted project, I jumped at the opportunity.”

Gibson and Robertson are studying how people align their dialogue, not only in the content and form of their utterances, but using eye contact. Fedorenko and Kanwisher will employ fMRI to discover key components of a conversation network in the cortex. Saxe will examine the development of conversational ability in toddlers using novel MRI techniques. Levy and Tenenbaum will complement these efforts to improve computational models of language processing and conversation.

The newest Targeted Project posits that the immune system can be harnessed to help treat behavioral symptoms of autism. Four labs — three in BCS and one at Harvard Medical School (HMS) — will study mechanisms by which peripheral immune cells can deliver a potentially therapeutic cytokine to the brain. A study by two of the collaborators, MIT associate professor Gloria Choi and HMS associate professor Jun Huh, showed that when IL-17a reaches excitatory neurons in a region of the mouse cortex, it can calm hyperactivity in circuits associated with social and repetitive behavior symptoms. Huh, an immunologist, will examine how IL-17a can get from the periphery to the brain, while Choi will examine how it has its neurological effects. Sur and MIT associate professor Myriam Heiman will conduct studies of cell types that bridge neural circuits with brain circulatory systems.

“It is quite amazing that we have a core of scientists working on very different things coming together to tackle this one common goal,” Choi says. “I really value that.”

Multiple mentors

While SCSB Targeted Projects unify labs around research, the center’s Simons Fellowships unify labs around young researchers, providing not only funding, but a pair of mentors and free-flowing interactions between their labs. Fellows also gain opportunities to inform and inspire their fundamental research by visiting with patients with autism, Sur says.

“The SCSB postdoctoral program serves a critical role in ensuring that a diversity of outstanding scientists are exposed to autism research during their training, providing a pipeline of new talent and creativity for the field,” adds Martin, of the Simons Foundation.

Simons Fellows praise the extra opportunities afforded by additional mentoring. Postdoc Alex Major was a Simons Fellow in Miller’s lab and that of Nancy Kopell, a mathematics professor at Boston University renowned for her modeling of the brain wave phenomena that the Miller lab studies experimentally.

“The dual mentorship structure is a very useful aspect of the fellowship” Major says. “It is both a chance to network with another PI and provides experience in a different neuroscience sub-field.”

Miller says co-mentoring expands the horizons and capabilities of not only the mentees but also the mentors and their labs. “Collaboration is 21st century neuroscience,” Miller says. “Some our studies of the brain have gotten too big and comprehensive to be encapsulated in just one laboratory. Some of these big questions require multiple approaches and multiple techniques.”

Desimone, who recently co-mentored Seng Bum (Michael Yoo) along with BCS and McGovern colleague Mehrdad Jazayeri in a project studying how animals learn from observing others, agrees.

“We hear from postdocs all the time that they wish they had two mentors, just in general to get another point of view,” Desimone says. “This is a really good thing and it’s a way for faculty members to learn about what other faculty members and their postdocs are doing.”

Indeed, the Simons Center model suggests that research can be very successful when it’s collaborative and social.

Margaret Livingstone awarded the 2024 Scolnick Prize in Neuroscience

by Jill Crittenden |

Today the McGovern Institute at MIT announces that the 2024 Edward M. Scolnick Prize in Neuroscience will be awarded to Margaret Livingstone, Takeda Professor of Neurobiology at Harvard Medical School. The Scolnick Prize is awarded annually by the McGovern Institute, for outstanding achievements in neuroscience.

“Margaret Livingstone’s driven curiosity and original experimental approaches have led to fundamental advances in our understanding of visual perception,” says Robert Desimone, director of the McGovern Institute and chair of the selection committee. “In particular, she has made major advances in resolving a long-standing debate over whether the brain domains and neurons that are specifically tuned to detect facial features are present from birth or arise from experience. Her developmental research shows that the cerebral cortex already contains topographic sensory maps at birth but that domain-specific maps, for example to recognize facial-features, require experience and sensory input to develop normally.”

“Margaret Livingstone’s driven curiosity and original experimental approaches have led to fundamental advances in our understanding of visual perception.” — Robert Desimone

Livingstone received a BS from MIT in 1972 and, under the mentorship of Edward Kravitz, a PhD in neurobiology from Harvard University in 1981. Her doctoral research in lobsters showed that the biogenic amines serotonin and octopamine control context-dependent behaviors such as offensive versus defensive postures. She followed up on this discovery as a postdoctoral fellow by researching biogenic amine signaling in learning and memory, with Prof. William Quinn at Princeton University. Using learning and memory mutants created in the fruit fly model she identified defects in dopamine-synthesizing enzymes and calcium-dependent enzymes that produce cAMP. Her results supported the then burgeoning idea that biogenic amines signal through second messengers enable behavioral plasticity.

To test whether biogenic amines also control neuronal function in mammals, Livingstone moved back to Harvard Medical School in 1983 to study the effects of sleep on visual processing with David Hubel, who was studying neuronal activity in the nonhuman primate visual cortex. Over the course of a 20-year collaboration, Livingstone and Hubel showed that the visual system is functionally and anatomically divided into parallel pathways that detect and process the distinct visual features of color, motion, and orientation.

Livingstone quickly rose through the academic ranks at Harvard to be appointed as an instructor and then assistant professor in 1983, associate professor in 1986 and full professor in 1988. With her own laboratory, Livingstone began to explore the organization of face-perception domains in the inferotemporal cortex of nonhuman primates. By combining single-cell recording and fMRI brain imaging data from the same animal, her then graduate student Doris Tsao, in collaboration with Winrich Freiwald, showed that an abundance of individual neurons within the face-recognition domain are tuned to a combination of facial features. These results helped to explain the long-standing question of how individual neurons show such exquisite selectivity to specific faces.

Three images of Mona Lisa, side by side, each with a different filter slightly obscuring the face.
Mona Lisa’s smile has been described as mysterious and fleeting because it seems to disappear when viewers look directly at it. Livingstone showed that Mona Lisa’s smile is more apparent in our peripheral vision than our central (or foveal) vision because our peripheral vision is more sensitive to low spatial frequencies, or shadows and shadings of black and white. These shadows make her lips seem to turn upward into a subtle smile. The three images above show the painting filtered to reveal very low spatial frequency features (left, with the smile more apparent) to high spatial frequency features (right, with the smile being less visible). Image: Margaret Livingstone

In researching face patches, Livingstone became fascinated with the question of whether face-perception domains are present from birth, as many scientists thought at the time. Livingstone and her postdoc Michael Arcaro carried out experiments that showed that the development of face patches requires visual exposure to faces in the early postnatal period. Moreover, they showed that entirely unnatural symbol-specific domains can form in animals that experienced intensive visual exposure to symbols early in development. Thus, experience is both necessary and sufficient for the formation of feature-specific domains in the inferotemporal cortex. Livingtone’s results support a consistent principle for the development of higher-level cortex, from a hard-wired sensory topographic map present at birth to the formation of experience-dependent domains that detect combined, stimulus-specific features.

Livingstone is also known for her scientifically based exploration of the visual arts. Her book “Vision and Art: The Biology of Seeing,” which has sold more than 40,000 copies to date, explores how both the techniques artists use and our anatomy and physiology influence our perception of art. Livingstone has presented this work to audiences around the country, from Pixar Studios, MicroSoft and IBM to The Metropolitan Museum of Art, The National Gallery and The Hirshhorn Museum.

In 2014, Livingstone was awarded the Takeda Professorship of Neurobiology at Harvard Medical School. She was awarded the Mika Salpeter Lifetime Achievement Award from the Society for Neuroscience in 2011, the Grossman Award from the Society of Neurological Surgeons in 2013 and the Roberts Prize for Best Paper in Physics in Medicine and Biology in 2013 and 2016. Livingstone was elected fellow of the American Academy of Arts and Sciences in 2018 and of the National Academy of Science in 2020. She will be awarded the Scolnick Prize in the spring of 2024.

The promise of gene therapy

by Robert Desimone |

Portrait of Bob Desimone wearing a suit and tie.
McGovern Institute Director Robert Desimone. Photo: Steph Stevens

As we start 2024, I hope you can join me in celebrating a historic recent advance: the FDA approval of Casgevy, a bold new treatment for devastating sickle cell disease and the world’s first approved CRISPR gene therapy.

Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, we are proud to share that this pioneering therapy licenses the CRISPR discoveries of McGovern scientist and Poitras Professor of Neuroscience Feng Zhang.

It is amazing to think that Feng’s breakthrough work adapting CRISPR-Cas9 for genome editing in eukaryotic cells was published only 11 years ago today in Science.

Incredibly, CRISPR-Cas9 rapidly transitioned from proof-of-concept experiments to an approved treatment in just over a decade.

McGovern scientists are determined to maintain the momentum!

 

Incredibly, CRISPR-Cas9 rapidly transitioned from proof-of-concept experiments to an approved treatment in just over a decade.

Our labs are creating new gene therapies that are already in clinical trials or preparing to enroll patients in trials. For instance, Feng Zhang’s team has developed therapies currently in clinical trials for lymphoblastic leukemia and beta thalassemia, while another McGovern researcher, Guoping Feng, the Poitras Professor of Brain and Cognitive Sciences at MIT, has made advancements that lay the groundwork for a new gene therapy to treat a severe form of autism spectrum disorder. It is expected to enter clinical trials later this year. Moreover, McGovern fellows Omar Abudayyeh and Jonathan Gootenberg created programmable genomic tools that are now licensed for use in monogenic liver diseases and autoimmune disorders.

These exciting innovations stem from your steadfast support of our high-risk, high-reward research. Your generosity is enabling our scientists to pursue basic research in other areas with potential therapeutic applications in the future, such as mechanisms of pain, addiction, the connections between the brain and gut, the workings of memory and attention, and the bi-directional influence of artificial intelligence on brain research. All of this fundamental research is being fueled by major new advances in technology, many of them developed here.

As we enter a new year filled with anticipation following our inaugural gene therapy, I want to express my heartfelt gratitude for your invaluable support in advancing our research programs. Your role in pushing our research to new heights is valued by all faculty, students, and researchers at the McGovern Institute. We can’t wait to share our continued progress with you.

Thank you again for partnering with us to make great scientific achievements possible.

With appreciation and best wishes,

Robert Desimone, PhD
Director, McGovern Institute
Doris and Don Berkey Professor of Neuroscience, MIT

Season’s Greetings from the McGovern Institute

by McGovern Institute |

This year’s holiday greeting (video above) was inspired by research conducted in John Gabrieli’s lab, which found that practicing mindfulness reduced children’s stress levels and negative emotions during the pandemic. These findings contribute to a growing body of evidence that practicing mindfulness can change patterns of brain activity associated with emotions and mental health.

Coloring is one form of mindfulness, or focusing awareness on the present. Visit our postcard collection to download and color your own brain-themed postcards and may the spirit of mindfulness bring you peace in the year ahead!

Video credits:
Joseph Laney (illustration)
JR Narrows, Space Lute (sound design)
Jacob Pryor (animation)

A mindful McGovern community

by Julie Pryor |

Mindfulness is the practice of maintaining a state of complete awareness of one’s thoughts, emotions, or experiences on a moment-to-moment basis. McGovern researchers have shown that practicing mindfulness reduces anxiety and supports emotional resilience.

In a survey distributed to the McGovern Institute community, 57% of the 74 researchers, faculty, and staff who responded, said that they practice mindfulness as a way to reduce anxiety and stress.

Here are a few of their stories.

Fernanda De La Torre

Portrait of a smiling woman leaning back against a railing.
MIT graduate student Fernanda De La Torre. Photo: Steph Stevens

Fernanda De La Torre is a graduate student in MIT’s Department of Brain and Cognitive Sciences, where she is advised by Josh McDermott.

Originally from Mexico, De La Torre took an unconventional path to her education in the United States, where she completed her undergraduate studies in computer science and math at Kansas State University. In 2019, she came to MIT as a postbaccalaureate student in the lab of Tomaso Poggio where she began working on deep-learning theory, an area of machine learning focused on how artificial neural networks modeled on the brain can learn to recognize patterns and learn.

A recent recipient of the prestigious Paul and Daisy Soros Fellowship for New Americans, De La Torre now studies multisensory integration during speech perception using deep learning models in Josh McDermott’s lab.

What kind of mindfulness do you practice, how often, and why?

Metta meditation is the type of meditation I come back to the most. I practice 2-3 times per week. Sometimes by joining Nikki Mirghafori’s Zoom calls or listening to her and other teachers’ recordings on AudioDharma. I practice because when I observe the patterns of my thoughts, I remember the importance of compassion, including self-compassion. In my experience, I find metta meditation is a wonderful way to cultivate the two: observation and compassion. 

When and why did you start practicing mindfulness?

My first meditation practice was as a first-year post-baccalaureate student here at BCS. Gal Raz (also pictured above) carried a lot of peace and attributed it to meditation; this sparked my curiosity. I started practicing more frequently last summer, after realizing my mental health was not in a good place.

How does mindfulness benefit your research at MIT?

This is hard to answer because I think the benefits of meditation are hard to measure. I find that meditation helps me stay centered and healthy, which can indirectly help the research I do. More directly, some of my initial grad school pursuits were fueled by thoughts during meditation but I ended up feeling that a lot of these concepts are hard to explore using non-philosophical approaches. So I think meditation is mainly a practice that helps my health, my relationships with others, and my relationship with work (this last one I find most challenging and personally unresolved). 

Adam Eisen

MIT graduate student Adam Eisen.

Adam Eisen is a graduate student in MIT’s Department of Brain and Cognitive Sciences, where he is co-advised by Ila Fiete (McGovern Institute) and Earl Miller (Picower Institute).

Eisen completed his undergraduate degree in Applied Mathematics & Computer Engineering at Queen’s University in Toronto, Canada. Prior to joining MIT, Eisen built computer vision algorithms at the solar aerial inspection company Heliolytics and worked on developing machine learning tools to predict disease outcomes from genetics at The Hospital for Sick Children.

Today, in the Fiete and Miller labs, Eisen develops tools for analyzing the flow of neural activity, and applies them to understand changes in neural states (such as from consciousness to anesthetic-induced unconsciousness).

What kind of mindfulness do you practice, how often, and why?

I mostly practice simple sitting meditation centered on awareness of senses and breathing. On a good week, I meditate about 3-5 times. The reason I practice are the benefits to my general experience of living. Whenever I’m in a prolonged period of consistent meditation, I’m shocked by how much more awareness I have about thoughts, feelings and sensations that are arising in my mind throughout the day. I’m also amazed by how much easier it is to watch my mind and body react to the context around me, without slipping into the usual patterns and habits. I also find mindful benefits in doing yoga, running and playing music, but the core is really centered on meditation practice.

When and why did you start practicing mindfulness?

I’ve been interested in mindfulness and meditation since undergrad as a path to investigating the nature of mind and thought – an interest which also led me into my PhD. I started practicing meditation more seriously at the start of the pandemic to get more first hand experience with what I had been learning about. I find meditation is one of those things where knowledge and theory can support the practice, but without the experiential component it’s very hard to really start to build an understanding of the core concepts at play.

How does mindfulness benefit your research at MIT?

Mindfulness has definitely informed the kinds of things I’m interested in studying and the questions I’d like to ask – largely in relation to the nature of conscious awareness and the flow of thoughts. Outside of that, I’d like to think that mindfulness benefits my general well-being and spiritual balance, which enables me to do better research.

 

Sugandha Sharma

Woman clasping hands in a yoga pose, looking directly into the camera.
MIT graduate student Sugandha Sharma. Photo: Steph Stevens

Sugandha (Su) Sharma is a graduate student in MIT’s Department of Brain and Cognitive Sciences (BCS), where she is co-advised by Ila Fiete (McGovern Institute) and Josh Tenenbaum (BCS).

Prior to joining MIT, she studied theoretical neuroscience at the University of Waterloo where she built neural models of context dependent decision making in the prefrontal cortex and spiking neuron models of bayesian inference, based on online learning of priors from life experience.

Today, in the Fiete and Tenenbaum labs, she studies the computational and theoretical principles underlying cognition and intelligence in the human brain.  She is currently exploring the coding principles in the hippocampal circuits implicated in spatial navigation, and their role in cognitive computations like structure learning and relational reasoning.

When did you start practicing mindfulness?

When I first learned to meditate, I was challenged to practice it every day for at least 3 months in a row. I took up the challenge, and by the end of it, the results were profound. My whole perspective towards life changed. It made me more empathetic — I could step in other people’s shoes and be mindful of their situations and feelings;  my focus shifted from myself to the big picture — it made me realize how insignificant my life was on the grand scale of the universe, and how it was worthless to be caught up in small things that I was usually worrying about. It somehow also brought selflessness to me. This experience hooked me to meditation and mindfulness for life!

What kind of mindfulness do you practice and why?

I practice mindfulness because it brings awareness. It helps me to be aware of myself, my thoughts, my actions, and my surroundings at each moment in my life, thus helping me stay in and enjoy the present moment. Awareness is of utmost importance since an aware mind always does the right thing. Imagine that you are angry, in that moment you have lost awareness of yourself. The moment you become aware of yourself; anger goes away. This is why sometimes counting helps to combat anger. If you start counting, that gives you time to think and become aware of yourself and your actions.

Meditating — sitting with my eyes closed and just observing (being aware of) my thoughts — is a yogic technique that helps me clear the noise in my mind and calm it down making it easier for me to be mindful not only while meditating, but also in general after I am done meditating. Over time, the thoughts vanish, and the mind becomes blank (noiseless). For this reason, practicing meditation regularly makes it easier for me to be mindful all the time.

An added advantage of yoga and meditation is that it helps combat stress by relaxing the mind and body. Many people don’t know what to do when they are stressed, but I am grateful to have this toolkit of yoga and meditation to deal with stressful situations in my life. They help me calm my mind in stressful situations and ensure that instead of reacting to a situation, I instead act mindfully and appropriately to make it right.

K. Lisa Yang Postbaccalaureate Program names new scholars

by Julie Pryor |

Funded by philanthropist Lisa Yang, the K. Lisa Yang Postbaccalaureate Scholar Program provides two years of paid laboratory experience, mentorship, and education to recent college graduates from backgrounds underrepresented in neuroscience. This year, two young researchers in McGovern Institute labs, Joseph Itiat and Sam Merrow, are the recipients of the Yang postbac program.

Itiat moved to the United States from Nigeria in 2019 to pursue a degree in psychology and cognitive neuroscience at Temple University. Today, he is a Yang postbac in John Gabrieli’s lab studying the relationship between learning and value processes and their influence on future-oriented decision-making. Ultimately, Itiat hopes to develop models that map the underlying mechanisms driving these processes.

“Being African, with limited research experience and little representation in the domain of neuroscience research,” Itiat says, “I chose to pursue a postbaccalaureate
research program to prepare me for a top graduate school and a career in cognitive neuroscience.”

Merrow first fell in love with science while working at the Barrow Neurological Institute in Arizona during high school. After graduating from Simmons University in Boston, Massachusetts, Merrow joined Guoping Feng’s lab as a Yang postbac to pursue research on glial cells and brain disorders. “As a queer, nonbinary, LatinX person, I have not met anyone like me in my field, nor have I had role models that hold a similar identity to myself,” says Merrow.

“My dream is to one day become a professor, where I will be able to show others that science is for anyone.”

Previous Yang postbacs include Alex Negron, Zoe Pearce, Ajani Stewart, and Maya Taliaferro.

What does the future hold for generative AI?

by Adam Zewe |

Speaking at the “Generative AI: Shaping the Future” symposium on Nov. 28, the kickoff event of MIT’s Generative AI Week, keynote speaker and iRobot co-founder Rodney Brooks warned attendees against uncritically overestimating the capabilities of this emerging technology, which underpins increasingly powerful tools like OpenAI’s ChatGPT and Google’s Bard.

“Hype leads to hubris, and hubris leads to conceit, and conceit leads to failure,” cautioned Brooks, who is also a professor emeritus at MIT, a former director of the Computer Science and Artificial Intelligence Laboratory (CSAIL), and founder of Robust.AI.

“No one technology has ever surpassed everything else,” he added.

The symposium, which drew hundreds of attendees from academia and industry to the Institute’s Kresge Auditorium, was laced with messages of hope about the opportunities generative AI offers for making the world a better place, including through art and creativity, interspersed with cautionary tales about what could go wrong if these AI tools are not developed responsibly.

Generative AI is a term to describe machine-learning models that learn to generate new material that looks like the data they were trained on. These models have exhibited some incredible capabilities, such as the ability to produce human-like creative writing, translate languages, generate functional computer code, or craft realistic images from text prompts.

In her opening remarks to launch the symposium, MIT President Sally Kornbluth highlighted several projects faculty and students have undertaken to use generative AI to make a positive impact in the world. For example, the work of the Axim Collaborative, an online education initiative launched by MIT and Harvard, includes exploring the educational aspects of generative AI to help underserved students.

The Institute also recently announced seed grants for 27 interdisciplinary faculty research projects centered on how AI will transform people’s lives across society.

In hosting Generative AI Week, MIT hopes to not only showcase this type of innovation, but also generate “collaborative collisions” among attendees, Kornbluth said.

Collaboration involving academics, policymakers, and industry will be critical if we are to safely integrate a rapidly evolving technology like generative AI in ways that are humane and help humans solve problems, she told the audience.

“I honestly cannot think of a challenge more closely aligned with MIT’s mission. It is a profound responsibility, but I have every confidence that we can face it, if we face it head on and if we face it as a community,” she said.

While generative AI holds the potential to help solve some of the planet’s most pressing problems, the emergence of these powerful machine learning models has blurred the distinction between science fiction and reality, said CSAIL Director Daniela Rus in her opening remarks. It is no longer a question of whether we can make machines that produce new content, she said, but how we can use these tools to enhance businesses and ensure sustainability. 

“Today, we will discuss the possibility of a future where generative AI does not just exist as a technological marvel, but stands as a source of hope and a force for good,” said Rus, who is also the Andrew and Erna Viterbi Professor in the Department of Electrical Engineering and Computer Science.

But before the discussion dove deeply into the capabilities of generative AI, attendees were first asked to ponder their humanity, as MIT Professor Joshua Bennett read an original poem.

Bennett, a professor in the MIT Literature Section and Distinguished Chair of the Humanities, was asked to write a poem about what it means to be human, and drew inspiration from his daughter, who was born three weeks ago.

The poem told of his experiences as a boy watching Star Trek with his father and touched on the importance of passing traditions down to the next generation.

In his keynote remarks, Brooks set out to unpack some of the deep, scientific questions surrounding generative AI, as well as explore what the technology can tell us about ourselves.

To begin, he sought to dispel some of the mystery swirling around generative AI tools like ChatGPT by explaining the basics of how this large language model works. ChatGPT, for instance, generates text one word at a time by determining what the next word should be in the context of what it has already written. While a human might write a story by thinking about entire phrases, ChatGPT only focuses on the next word, Brooks explained.

ChatGPT 3.5 is built on a machine-learning model that has 175 billion parameters and has been exposed to billions of pages of text on the web during training. (The newest iteration, ChatGPT 4, is even larger.) It learns correlations between words in this massive corpus of text and uses this knowledge to propose what word might come next when given a prompt.

The model has demonstrated some incredible capabilities, such as the ability to write a sonnet about robots in the style of Shakespeare’s famous Sonnet 18. During his talk, Brooks showcased the sonnet he asked ChatGPT to write side-by-side with his own sonnet.

But while researchers still don’t fully understand exactly how these models work, Brooks assured the audience that generative AI’s seemingly incredible capabilities are not magic, and it doesn’t mean these models can do anything.

His biggest fears about generative AI don’t revolve around models that could someday surpass human intelligence. Rather, he is most worried about researchers who may throw away decades of excellent work that was nearing a breakthrough, just to jump on shiny new advancements in generative AI; venture capital firms that blindly swarm toward technologies that can yield the highest margins; or the possibility that a whole generation of engineers will forget about other forms of software and AI.

At the end of the day, those who believe generative AI can solve the world’s problems and those who believe it will only generate new problems have at least one thing in common: Both groups tend to overestimate the technology, he said.

“What is the conceit with generative AI? The conceit is that it is somehow going to lead to artificial general intelligence. By itself, it is not,” Brooks said.

Following Brooks’ presentation, a group of MIT faculty spoke about their work using generative AI and participated in a panel discussion about future advances, important but underexplored research topics, and the challenges of AI regulation and policy.

The panel consisted of Jacob Andreas, an associate professor in the MIT Department of Electrical Engineering and Computer Science (EECS) and a member of CSAIL; Antonio Torralba, the Delta Electronics Professor of EECS and a member of CSAIL; Ev Fedorenko, an associate professor of brain and cognitive sciences and an investigator at the McGovern Institute for Brain Research at MIT; and Armando Solar-Lezama, a Distinguished Professor of Computing and associate director of CSAIL. It was moderated by William T. Freeman, the Thomas and Gerd Perkins Professor of EECS and a member of CSAIL.

The panelists discussed several potential future research directions around generative AI, including the possibility of integrating perceptual systems, drawing on human senses like touch and smell, rather than focusing primarily on language and images. The researchers also spoke about the importance of engaging with policymakers and the public to ensure generative AI tools are produced and deployed responsibly.

“One of the big risks with generative AI today is the risk of digital snake oil. There is a big risk of a lot of products going out that claim to do miraculous things but in the long run could be very harmful,” Solar-Lezama said.

The morning session concluded with an excerpt from the 1925 science fiction novel “Metropolis,” read by senior Joy Ma, a physics and theater arts major, followed by a roundtable discussion on the future of generative AI. The discussion included Joshua Tenenbaum, a professor in the Department of Brain and Cognitive Sciences and a member of CSAIL; Dina Katabi, the Thuan and Nicole Pham Professor in EECS and a principal investigator in CSAIL and the MIT Jameel Clinic; and Max Tegmark, professor of physics; and was moderated by Daniela Rus.

One focus of the discussion was the possibility of developing generative AI models that can go beyond what we can do as humans, such as tools that can sense someone’s emotions by using electromagnetic signals to understand how a person’s breathing and heart rate are changing.

But one key to integrating AI like this into the real world safely is to ensure that we can trust it, Tegmark said. If we know an AI tool will meet the specifications we insist on, then “we no longer have to be afraid of building really powerful systems that go out and do things for us in the world,” he said.

Ariel Furst and Fan Wang receive 2023 National Institutes of Health awards

by MIT School of Science |

The National Institutes of Health (NIH) has awarded grants to MIT’s Ariel Furst and Fan Wang, through its High-Risk, High-Reward Research program. The NIH High-Risk, High-Reward Research program awarded 85 new research grants to support exceptionally creative scientists pursuing highly innovative behavioral and biomedical research projects.

Ariel Furst was selected as the recipient of the NIH Director’s New Innovator Award, which has supported unusually innovative research since 2007. Recipients are early-career investigators who are within 10 years of their final degree or clinical residency and have not yet received a research project grant or equivalent NIH grant.

Furst, the Paul M. Cook Career Development Assistant Professor of Chemical Engineering at MIT, invents technologies to improve human and environmental health by increasing equitable access to resources. Her lab develops transformative technologies to solve problems related to health care and sustainability by harnessing the inherent capabilities of biological molecules and cells. She is passionate about STEM outreach and increasing the participation of underrepresented groups in engineering.

After completing her PhD at Caltech, where she developed noninvasive diagnostics for colorectal cancer, Furst became an A. O. Beckman Postdoctoral Fellow at the University of California at Berkeley. There she developed sensors to monitor environmental pollutants. In 2022, Furst was awarded the MIT UROP Outstanding Faculty Mentor Award for her work with undergraduate researchers. She is a now a 2023 Marion Milligan Mason Awardee, a CIFAR Azrieli Global Scholar for Bio-Inspired Solar Energy, and an ARO Early Career Grantee. She is also a co-founder of the regenerative agriculture company, Seia Bio.

Fan Wang received the Pioneer Award, which has been challenging researchers at all career levels to pursue new directions and develop groundbreaking, high impact approaches to a broad area of biomedical and behavioral sciences since 2004.

Wang, a professor in the Department of Brain and Cognitive Sciences and an investigator in the McGovern Institute for Brain Research, is uncovering the neural circuit mechanisms that govern bodily sensations, like touch, pain, and posture, as well as the mechanisms that control sensorimotor behaviors. Researchers in the Wang lab aim to generate an integrated understanding of the sensation-perception-action process, hoping to find better treatments for diseases like chronic pain, addiction, and movement disorders. Wang’s lab uses genetic, viral, in vivo large-scale electrophysiology and imaging techniques to gain traction in these pursuits.

Wang obtained her PhD at Columbia University, working with Professor Richard Axel. She conducted her postdoctoral work at Stanford University with Mark Tessier-Lavigne, and then subsequently joined Duke University as faculty in 2003. Wang was later appointed as the Morris N. Broad Distinguished Professor of Neurobiology at the Duke University School of Medicine. In January 2023, she joined the faculty of the MIT School of Science and the McGovern Institute.

The High-Risk, High-Reward Research program is funded through the NIH Common Fund, which supports a series of exceptionally high-impact programs that cross NIH Institutes and Centers.

“The HRHR program is a pillar for innovation here at NIH, providing support to transformational research, with advances in biomedical and behavioral science,” says Robert W. Eisinger, acting director of the Division of Program Coordination, Planning, and Strategic Initiatives, which oversees the NIH Common Fund. “These awards align with the Common Fund’s mandate to support science expected to have exceptionally high and broadly applicable impact.”

NIH issued eight Pioneer Awards, 58 New Innovator Awards, six Transformative Research Awards, and 13 Early Independence Awards in 2023. Funding for the awards comes from the NIH Common Fund; the National Institute of General Medical Sciences; the National Institute of Mental Health; the National Library of Medicine; the National Institute on Aging; the National Heart, Lung, and Blood Institute; and the Office of Dietary Supplements.

Twelve with MIT ties elected to the National Academy of Medicine for 2023

by MIT School of Science |

The National Academy of Medicine announced the election of 100 new members to join their esteemed ranks in 2023, among them five MIT faculty members and seven additional affiliates.

MIT professors Daniel Anderson, Regina Barzilay, Guoping Feng, Darrell Irvine, and Morgen Shen were among the new members. Justin Hanes PhD ’96, Said Ibrahim MBA ’16, and Jennifer West ’92, along with three former students in the Harvard-MIT Program in Health Sciences and Technology (HST) — Michael Chiang, Siddhartha Mukherjee, and Robert Vonderheide — were also elected, as was Yi Zhang, an associate member of The Broad Institute of MIT and Harvard.

Election to the academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service, the academy noted in announcing the election of its new members.

MIT faculty

Daniel G. Anderson, professor in the Department of Chemical Engineering and the Institute for Medical Engineering and Science, was elected “for pioneering the area of non-viral gene therapy and cellular delivery. His work has resulted in fundamental scientific advances; over 500 papers, patents, and patent applications; and the creation of companies, products, and technologies that are now in the clinic.” Anderson is an affiliate of the Broad Institute of MIT and Harvard and of the Ragon Institute at MGH, MIT and Harvard.

Regina Barzilay, the School of Engineering Distinguished Professor for AI and Health within the Department of Electrical Engineering and Computer Science at MIT, was elected “for the development of machine learning tools that have been transformational for breast cancer screening and risk assessment, and for the development of molecular design tools broadly utilized for drug discovery.” Barzilay is the AI faculty lead within the MIT Abdul Latif Jameel Clinic for Machine Learning in Health and an affiliate of the Computer Science and Artificial Intelligence Laboratory and Institute for Medical Engineering and Science.

Guoping Feng, the associate director of the McGovern Institute for Brain Research, James W. (1963) and Patricia T. Professor of Neuroscience in MIT’s Department of Brain and Cognitive Sciences, and an affiliate of the Broad Institute of MIT and Harvard, was elected “for his breakthrough discoveries regarding the pathological mechanisms of neurodevelopmental and psychiatric disorders, providing foundational knowledges and molecular targets for developing effective therapeutics for mental illness such as OCD, ASD, and ADHD.”

Darrell J. Irvine ’00, the Underwood-Prescott Professor of Biological Engineering and Materials Science at MIT and a member of the Koch Institute for Integrative Cancer Research, was elected “for the development of novel methods for delivery of immunotherapies and vaccines for cancer and infectious diseases.”

Morgan Sheng, professor of neuroscience in the Department of Brain and Cognitive Sciences, with affiliations in the McGovern Institute and The Picower Institute for Learning and Memory at MIT, as well as the Broad Institute of MIT and Harvard, was elected “for transforming the understanding of excitatory synapses. He revealed the postsynaptic density as a protein network controlling synaptic signaling and morphology; established the paradigm of signaling complexes organized by PDZ scaffolds; and pioneered the concept of localized regulation of mitochondria, apoptosis, and complement for targeted synapse elimination.”

Additional MIT affiliates

Michael F. Chiang, a former student in the Harvard-MIT Program in Health Sciences and Technology (HST) who is now director of the National Eye Institute of the National Institutes of Health, was honored “for pioneering applications of biomedical informatics to ophthalmology in artificial intelligence, telehealth, pediatric retinal disease, electronic health records, and data science, including methodological and diagnostic advances in AI for pediatric retinopathy of prematurity, and for contributions to developing and implementing the largest ambulatory care registry in the United States.”

Justin Hanes PhD ’96, who earned his PhD from the MIT Department of Chemical Engineering and is now a professor at Johns Hopkins University, was honored “for pioneering discoveries and inventions of innovative drug delivery technologies, especially mucosal, ocular, and central nervous system drug delivery systems; and for international leadership in research and education at the interface of engineering, medicine, and entrepreneurship, leading to clinical translation of drug delivery technologies.”

Said Ibrahim MBA ’16, a graduate of the MIT Sloan School of Management who is now a senior vice president and chair, department of medicine at the Zucker School of Medicine at Hofstra/Northwell, was honored for influential “health services research on racial disparities in elective joint replacement that has provided a national model for advancing health equity research beyond the identification of inequities and toward their remediation, and for his research that has been leveraged to engage diverse and innovative emerging scholars.”

Siddhartha Mukherjee, a former student in HST who is now an associate professor of medicine at Columbia University School of Medicine, was honored “for contributing important research in the immunotherapy of myeloid malignancies, such as acute myeloid leukemia, for establishing international centers for immunotherapy for childhood cancers, and for the discovery of tissue-resident stem cells.”

Robert H. Vonderheide, a former student in HST who is now a professor and vice dean at the Perelman School of Medicine and vice president of cancer programs at the University of Pennsylvania Health System, was honored “for developing immune combination therapies for patients with pancreatic cancer by driving proof-of-concept from lab to clinic, then leading national, randomized clinical trials for therapy, maintenance, and interception; and for improving access of minority individuals to clinical trials while directing an NCI comprehensive cancer center.”

Jennifer West ’92, a graduate of the MIT Department of Chemical Engineering who is now a professor of biomedical engineering and dean of the School of Engineering and Applied Science at the University of Virginia at Charlottesville, was honored “for the invention, development, and translation of novel biomaterials including bioactive, photopolymerizable hydrogels and theranostic nanoparticles.”

Yi Zhang, associate member of the Broad Institute, was honored “for making fundamental contributions to the epigenetics field through systematic identification and characterization of chromatin modifying enzymes, including EZH2, JmjC, and Tet. His proof-of-principle work on EZH2 inhibitors led to the founding of Epizyme and eventual making of tazemetostat, a drug approved for epithelioid sarcoma and follicular lymphoma.”

“It is my honor to welcome this truly exceptional class of new members to the National Academy of Medicine,” said NAM President Victor J. Dzau. “Their contributions to health and medicine are unparalleled, and their leadership and expertise will be essential to helping the NAM tackle today’s urgent health challenges, inform the future of health care, and ensure health equity for the benefit of all around the globe.”